NCT05014555View on ClinicalTrials.gov

Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease

UnknownOBSERVATIONAL
Enrollment

400

Participants

Timeline

Start Date

July 5, 2023

Primary Completion Date

January 31, 2024

Study Completion Date

January 31, 2024

Conditions
Inflammatory Bowel Diseases
Interventions
BIOLOGICAL

COVID-19 Vaccine

Three-dose mRNA COVID-19 vaccine per standard of care

Trial Locations (4)

32224

Mayo Clinic Jacksonville, FL, Jacksonville

53726

University of Wisconsin, Madison

70809

GI Alliance, Baton Rouge

76092

GI Alliance, Southlake

Sponsors

Lead Sponsor

GI Alliance

Collaborators (1)

Mayo Clinic
All Listed Sponsors
collaborator

Janssen, LP

INDUSTRY

collaborator

University of Wisconsin, Madison

OTHER

collaborator

Mayo Clinic

OTHER

lead

GI Alliance

OTHER

NCT05014555 - Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease | Biotech Hunter | Biotech Hunter